We compared outcomes after hematopoietic cell transplantation in patients of African American (n=84) and Caucasian (n=215) descent with severe aplastic anemia. African Americans and Caucasians were matched for age, donor-recipient HLA match, graft type and transplantation year. The median follow-up of surviving patients was 5 years. In multivariate analysis, overall mortality risks were higher for African Americans compared to Caucasians, relative risk [RR] 1.73, p=0.01. The 5-year probabilities of overall survival adjusted for interval from diagnosis to transplantation, and performance score was 58% for African Americans and 73% for Caucasians. The day-100 cumulative incidence of grade III-IV, but not grade II-IV acute graft versus host disease (GVHD) was higher in African Americans compared to Caucasians (29% vs. 13%, p=0.006). Though the 5year cumulative incidence of chronic GVHD was not significantly different between the racial groups, African Americans were more likely to have extensive chronic GVHD compared to Caucasians (72% vs. 49%, p=0.06). Survival differences between Caucasians and African Americans can be attributed to multiple factors. Our data suggest some of the observed survival differences between Caucasians and African Americans may be explained by higher rates of acute GVHD and severity of chronic GVHD.
Introduction
Severe aplastic anemia is a rare hematologic disease that results in immune-mediated bone marrow failure; it has an incidence of approximately 2 per million per year. [1] Severe aplastic anemia is the most common non-malignant hematologic indication for hematopoietic cell transplantation, [2] and transplantation is curative. Survival after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia has improved over time such that survival rates now approach 90% after HLA-matched sibling and 75% after HLA-matched unrelated donor bone marrow transplantation. [3] [4] [5] [6] Several reports also support bone marrow as the preferred source of stem cells. [7, 8] Transplantation of peripheral blood progenitor cells from HLA-matched siblings and adult unrelated donors is associated with higher mortality rates secondary to a higher incidence of chronic graftversus-host disease (GVHD). [5, 9, 10] To our knowledge, no reports have explored the effect of patient race on survival after hematopoietic stem cell transplantation for severe aplastic anemia. Though aplastic anemia in the U.S. is predominantly a disease of Caucasians, it also occurs in African Americans albeit less frequently. Two independent studies, one from a single institution [11] and the other from the Center for International Blood and Marrow Transplant Research (CIBMTR) [12] reported lower overall survival rates for African Americans compared to Caucasians with hematologic malignancies after allogeneic hematopoietic stem cell transplantation. Neither study identified an etiology for the observed higher mortality in African Americans. To our knowledge there are no reports that have explored the effect of race on survival after allogeneic transplantation for severe aplastic anemia. Therefore, the current analysis was undertaken to address two objectives: first, to compare overall survival rates after HLAmatched sibling and adult unrelated donor transplantation for severe aplastic anemia in patients of African American and Caucasian descent and second, if differences exist in survival between the racial groups, to identify factors associated with higher mortality.
Methods

Data source
The CIBMTR is a voluntary working group of more than 450 transplant centers worldwide that contribute data prospectively on consecutive transplants performed at each center. All patients are followed annually until death, and data are collected on standardized reporting forms with compliance monitored by audits and computerized error checks. Observational studies conducted by the CIBMTR are performed in compliance with Health Insurance Portability and Accountability Act regulations as a public health authority and also in compliance with applicable federal regulations pertaining to the protection of human research participants, as determined by continuous review by the Institutional Review Boards of the National Marrow Donor Program and the Medical College of Wisconsin.
Inclusion and exclusion criteria
Included were patients with severe aplastic anemia of Caucasian or African American descent. Patients received grafts from HLA-matched siblings or adult unrelated donors. All transplants were performed in the U.S. between 1990 and 2008. Recipients of mismatched related donor and umbilical cord blood transplants were excluded, as there were too few patients of African American descent. Patients of Asian descent were also excluded, as there were too few.
Outcomes
The primary endpoint was overall survival, defined as death from any cause. Neutrophil recovery was defined as the first day of having an absolute neutrophil count of ≥500 cells per cubic millimeter for three consecutive days. Platelet recovery was defined as the recovery of greater than 20,000 platelets per cubic millimeter, unsupported by transfusion for seven days. Primary graft failure was defined as failure to achieve absolute neutrophil count ≥500 cells per cubic millimeter. Secondary graft failure was defined as the sustained loss of neutrophil counts to <500 cells per cubic millimeter after initial neutrophil recovery. Acute and chronic GVHD were graded using standard criteria. [13] [14] [15] 
Statistical analysis
The chi-square statistic was used to compare categorical variables. African Americans were matched to Caucasians based on factors known to be associated with survival after allogeneic transplantation for severe aplastic anemia. These included: age at transplantation (±3 years), [16, 17] donor type (HLA-matched sibling, matched unrelated donor, mismatched unrelated donor) [18] , graft-type (bone marrow or peripheral blood progenitor cells) [5] and transplant year (±1 year). [19] Eighty-four African Americans were matched to 215 Caucasians. Thirty-nine African Americans were matched to 156 Caucasians (1 case to 4 controls), 14 African Americans were matched to 42 Caucasians (1 case to 3 controls), 22 African Americans were matched to 44 Caucasians (1 case to 2 controls), 9 African Americans were matched to 9 Caucasians (1 case to 1 control).
The probability of overall survival was calculated with the Kaplan-Meier estimator. [20] Probabilities of neutrophil and platelet recovery, acute GVHD and chronic GVHD were calculated with the cumulative incidence estimator to accommodate competing risks. [20] In all analyses, data on patients without an event were censored at last follow-up. Multivariate analyses using marginal Cox model for matched data [21] were built for overall mortality, acute GVHD and chronic GVHD. Results are expressed as relative risks (RR) with 95% confidence intervals. For neutrophil and platelet recovery, conditional logistic regression was built. Results are expressed as an odds ratio (OR) with 95% confidence intervals.
For all outcomes of interest, the effect of patient race (African American vs. Caucasian) was held in all models regardless of level of significance.
Step-wise selection procedure was used to identify other variables with a significance level 0.05. Variables that attained statistical significance were retained in multivariate models. Individual covariates were entered as categorical variables as shown in Table 1 . Patient and disease characteristics tested included performance score (90-100 vs. <90), time from diagnosis to transplantation (<6 months vs. ≥ 6 months), and cytomegalovirus serostatus (recipient / donor seronegative vs. recipient seropositive / donor seronegative vs. recipient seronegative /donor seropositive vs. recipient / donor seropositive). There were differences in type of conditioning regimen by donor type. Therefore, regimens were grouped as follows: cyclophosphamide alone (sibling donor) vs. cyclophosphamide + anti-thymocyte globulin ATG (sibling donor) vs. cyclophosphamide + irradiation (sibling donor) vs. other regimens (sibling donor) vs. cyclophosphamide + irradiation (unrelated donor). GVHD prophylaxis was tested as follows: ex vivo T-depletion vs. tacrolimus-containing vs. cyclosporine-containing regimens. There were no significant first order interactions between the main effect variable (African Americans vs. Caucasians) and the other variables retained in the final multivariate model. We tested for an effect of transplant center on survival and found none. [22] All P values are two-sided. Analyses were performed using SAS 9.2 (SAS Institute, Cary, N.C.).
Results
Patients, disease and transplant characteristics are shown in Table 1 ; 84 African Americans (cases) were matched to 215 Caucasians (controls) on age, donor and graft type and transplant year. Ninety transplant centers contributed patients; 80 contributed Caucasian and 47 contributed African American patients. The median age of both cases and controls was 17 years at transplantation. The median interval from diagnosis to transplantation differed by donor type; 1.5 months for recipients of HLA-matched sibling and 13 months for recipients of unrelated donor transplant. However, there were no significant differences in the interval from diagnosis to transplantation between African Americans and Caucasians after matching for donor type and donor-recipient HLA-match; the median time was 4 months in both groups (p=0.24). Seventy percent of patients of both races had performance scores of 90 or 100 at transplantation. The most common conditioning regimen that was used for HLAmatched sibling transplantation was cyclophosphamide and ATG, and for unrelated donor transplantation, cyclophosphamide, total body irradiation (TBI) and ATG. Forty-five percent of transplants utilized grafts from adult unrelated donors and 55% from HLA-matched siblings. Fifty-four percent of unrelated donor-recipient pairs were HLA-mismatched at one or more HLA-loci. Forty-six patients were mismatched at one HLA locus, and nineteen were mismatched at two or more HLA-loci. Bone marrow was the predominant source of stem cells. Ten percent of HLA-matched sibling grafts and 9% of unrelated donor grafts were Tcell depleted (ex vivo). The remaining patients received tacrolimus-containing or cyclosporine-containing GVHD prophylaxis. The median follow-up of both African Americans and Caucasians was 5 years.
Hematopoietic recovery
Eighty-one of eighty-four African Americans and two hundred-three of two hundred-fifteen Caucasians achieved neutrophil recovery. The day-28 cumulative incidence of neutrophil recovery for African Americans and Caucasians was 88% (95% CI 80%-95%) and 89% (95% CI 76%-100%), respectively (p=0.88). In multivariate analysis, the likelihood of neutrophil recovery did not differ significantly for African Americans and Caucasians (OR 1.03, 95% CI 0.46 -2.33, p=0.94). Sixty-eight of eighty-four African Americans and one hundred and seventy-seven of two hundred-fifteen Caucasians achieved platelet recovery.
The day-100 cumulative incidence of platelet recovery was 77% (95% CI 63%-91%) for African Americans and 76% (95% CI 57%-85%) for Caucasians (p=0.91). In multivariate analysis, the likelihood of platelet recovery for African Americans compared to Caucasians was not significantly different (OR 0.93, 95% CI 0.45 -1.96, p=0.86).
Primary or secondary graft failure did not differ by race. Primary graft failure occurred in 12 Caucasians and 11 of 12 patients are dead including two, who received a second allogeneic transplant from their initial donor. None of the African Americans with primary graft failure (n=3) received a second transplant and are dead. Secondary graft failure occurred in 13 of 203 (6%) Caucasians; all patients received a second transplant, 11 from their initial donor, and four patients are dead. Secondary graft failure occurred in 7 of 81 (9%) African Americans; 6 of 7 patients are dead with only two patients having received a second transplant.
Acute and chronic graft-versus-host disease
Thirty-six of eighty-four African Americans and ninety-three of two hundred-fifteen Caucasians developed grade II-IV GVHD. There were no significant differences in grade II-IV risks between Caucasians and African Americans ( Table 2 ). The day-100 cumulative incidence of grade II-IV acute GVHD was 43% (95% CI 35%-50%) and 39% (95% CI 28%-50%) for African Americans and Caucasians, respectively (p=0.60). Twenty-five African Americans and twenty-one Caucasians developed grade III-IV acute GVHD. The day-100 cumulative incidence of grade III-IV acute GVHD was significantly higher for African Americans 29% (95% CI 18%-39%) compared to Caucasians 13% (95% CI 8%-18%), (p=0.006).
Twenty-seven of eighty-four African Americans and sixty-four of two hundred-fifteen Caucasians developed chronic GVHD. The 5-year cumulative incidence of chronic GVHD was 36% (95% CI 24%-48%) for African Americans and 30% (95% CI 23%-37%) for Caucasians (p=0.36). However, among those patients who developed chronic GVHD, extensive chronic GVHD was more common in African Americans (18 of 25; 72%) compared to Caucasians (33 of 67; 49%), p=0.06.
Independent of patient race, risks of grade II-IV acute GVHD were lower with tacrolimuscontaining regimens compared to cyclosporine-containing regimens (RR 0.45, 95% CI 0.24 -0.84, p=0.01). Transplant-conditioning regimen was also associated with higher risks of grade II-IV acute and chronic GVHD; transplant-conditioning regimen was a surrogate for donor source.
Overall Mortality
Thirty-seven of eighty-four African Americans and fifty-six of two hundred and fifteen Caucasians are dead. In multivariate analysis, overall mortality risks were higher in African Americans, adjusted for performance score and interval from diagnosis to transplantation, the other variables significantly associated with mortality risks ( Table 2 ). We also explored for differences in the pattern and timing of mortality in African Americans compared to Caucasians. Higher mortality rates among African Americans were observed during the early (OR 2.33, 95% CI 1.15 -4.75, p=0.02 at 3-months) as well as the later post-transplant period (OR 2.62, 95% CI 1.33 -5.15, p=0.005 at 12-months) compared to Caucasians. The 5-year probability of overall survival adjusted for interval from diagnosis to HCT, and performance score, was 58% (95% CI 48%-68%) for African Americans and 73% (95% CI 67%-79%) for Caucasians ( Figure 1 ). The adjusted overall survival was lower for African Americans compared to Caucasians for HLA-matched sibling and adult unrelated donor transplants (Figure 2A and 2B) .
The causes of death for the two racial groups are shown in Table 3 . The proportion of GVHD-related deaths was higher in African Americans than Caucasians (30% vs. 14%). Three Caucasians died of secondary malignancy; each had received irradiation-containing transplant conditioning regimens whereas this was not reported as a cause of death in African Americans. There were no significant differences between African Americans and Caucasians in deaths from graft failure, adult respiratory distress syndrome, organ failure, infection, or hemorrhage.
Discussion
The current analyses demonstrate lower survival rates in African Americans with severe aplastic anemia compared to Caucasians after allogeneic transplantation after adjusting for age, performance score, interval from diagnosis to transplant, donor source, donor-recipient HLA disparity, graft source and transplant period. By performing a matched pair analysis we ensured patient, disease and transplant characteristics between the racial groups were not significantly different. The observed excess mortality in African Americans occurred during both the early and the later post-transplant periods; we observed differences in survival as early as 3-months post-transplantation. Lower survival rates in African Americans, have been reported after allogeneic transplantation for hematologic malignancies. To our knowledge, this is the first report for severe aplastic anemia, the most common hematologic non-malignant indication for allogeneic transplantation. The observed difference in survival can be attributed to several unmeasured factors including polymorphism at non-HLA loci, disparities in access to health care, health behaviors including compliance and environmental factors and, measured factors like the severity of GVHD and socio-economic status.
Severe aplastic anemia is a good model to study, as there is no graft-versus-leukemia benefit, and patients with SAA derive no benefit from GVHD. [23] In the current analysis, African Americans were more likely to report grade III-IV acute GVHD and severe chronic GVHD compared to Caucasians. There are several reports on the adverse effect of GVHD and in particular severe GVHD on survival after transplantation. [24, 25] We observed lower risks of grade II-IV acute GVHD with tacrolimus-containing GVHD prophylaxis and its effect was independent of race. Acute GVHD is a known risk factor for chronic GVHD and the pre-emptive use of tacrolimus-containing GVHD prophylaxis regimens may lower acute and chronic GVHD in African Americans. Consistent with published reports, the risk of acute and chronic GVHD was higher after unrelated donor transplants compared to HLAmatched sibling transplants. In the current analysis, cases and controls were matched to donor type and the observed higher rate of grade III-IV acute GVHD cannot be attributed to donor type. We explored for an effect of transplant center and transplant period on survival and found none.
An earlier CIBMTR report evaluated the effect of race and socio-economic status in over 6000 recipients of adult unrelated donor transplants for hematologic malignancies. [12] In that report, lower survival in African Americans was not explained by socio-economic status as determined by their income. Rather patients with incomes in the lowest quartile (less than $34,700) were at higher risk for mortality (RR 1.15, p=0.005) and the effect of income on survival was independent of race. In the current analysis, data on patient/family income was available for only 40% of the study population (38% of African Americans and 41% of Caucasians). In that subset, the mean income of African Americans was lower compared to Caucasians ($38,100 vs. $47,300; p=0.02) and may explain some of the excess mortality in African Americans. The relatively small samples size in the current analysis prevented us from examining further for an effect of income on transplant outcomes.
There are several unmeasured factors that may have contributed to lower survival rates in African Americans. We performed a controlled analysis by matching African Americans and Caucasians for donor-recipient HLA disparity and considered matching at HLA-A, -B, -C and -DRB1 loci, the accepted standard when selecting unrelated donors. Although leukocyte telomere length is associated with lower survival in patients with severe aplastic anemia receiving immunosuppressive therapy, [26] there are no reports that describe the effect of telomere length on survival after transplantation for severe aplastic anemia. Exploration for the effect of genetic polymorphism is beyond the scope of the current study; polymorphisms in CYP3A are more frequent in African Americans and may have led to variable response to the calcineurin-inhibitors used to prevent GVHD. [27] Access to health care during post-transplant follow-up, may have contributed to some the excess mortality in African Americans. However, mortality rates were higher in the early post-transplant period as well, when most receive inpatient care.
Our findings suggest that despite improvements in survival after HLA-matched sibling and adult unrelated donor transplantation for severe aplastic anemia, survival rates of African Americans are substantially lower than Caucasians. The findings of the current analysis should raise awareness, an important first-step. While tacrolimus-containing GVHD prophylaxis may lower acute GVHD risks and consequently lower some of the excess mortality, our findings highlight a problem for a disease in which care providers have come to accept high survival rates after allogeneic transplantation. Only through carefully planned prospective studies that address societal and medical issues can we identify factors that adversely affect survival in African Americans with severe aplastic anemia. The adjusted probability of overall survival of patients by patient race. The 5-year probability of overall survival, adjusted for interval from diagnosis to transplantation and performance score, was lower for African Americans 58% (95% CI 48%-68%) compared to Caucasians 73% (95% CI 67%-79%). Figure 2A : The adjusted probability of overall survival of patients after HLA-matched sibling donor transplantation by patient race. The 5-year probability of overall survival, adjusted for interval from diagnosis to transplantation and performance score, was lower for African Americans 70% (95% CI 57%-83%) compared to Caucasians 86% (95% CI 79%-92%). Figure 2B : The adjusted probability of overall survival of patients after unrelated donor transplantation by patient race. The 5-year probability of overall survival, adjusted for interval from diagnosis to transplantation and performance score, was lower for African Americans 43% (95% CI 28%-59%) compared to Caucasians 57% (95% CI 47%-67%). 
